Free HIV Antiretroviral Therapy Enhances Adherence among Individuals on Stable Treatment: Implications for Potential Shortfalls in Free Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Byakika Tusiime, Jayne ^a   Polley, Eric C ^b   Oyugi, Jessica H ^a   Bangsberg, David R ^c  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG COST; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MARGINAL STRUCTURAL MODEL; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; STATISTICAL MODEL; TREATMENT DURATION; UGANDA; VIRUS LOAD; VISUAL ANALOG SCALE;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS;

EID: 84883499664     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070375     Document Type: Article

References (32)

1. WHO (2006) Progress on Global Access to HIV Antiretroviral Therapy- A Report on "3 by 5" and Beyond.
2. WHO (2007) Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector.
3. WHO (2009) Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report. Geneva: World Health Organization/UNAIDS/UNICEF.
4. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, et al. (2005) Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 16: 38-41.
5. Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, et al. (2003) Adherence to HAART and its principal determinants in a cohort of Senegalese adults. Aids 17 Suppl 3: S103-108.
6. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, et al. (2004) Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 20: 1053-1056.
7. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, et al. (2005) Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 10: 464-470.
8. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 34: 281-288.
9. Robins JM, Hernan MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
10. Robins J, (1999) Association, Causation, and Marginal Structural Models. Synthese 121: 151-179.
11. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, et al. (2003) Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694.
12. Hernan MA, Brumback B, Robins JM, (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570.
13. Petersen ML, Wang Y, van der Laan MJ, Bangsberg DR, (2006) Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr 43 Suppl 1: S96-S103.
14. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, et al. (2007) Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis 45: 908-915.
15. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100-1102.
16. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. Aids 21: 965-971.
17. Molinaro A, van der Laan MJ (2004) Deletion/substitution/addition algorithm for partitioning the covariate space in prediction. Technical report, Division of Biostatistics, University of California, Berkeley.
18. Sinisi S, van der Laan MJ, (2004) The deletion/substitution/addition algorithm in loss function based estimation: Applications in genomics. Journal of Statistical Methods in Molecular Biology 3.
19. Gruber S, van der Laan MJ (August 2009) Targeted Maximum Likelihood Estimation: A Gentle Introduction. UC Berkeley Division of Biostatistics Working Paper Series Working Paper 252. Available: http://www.bepress.com/ucbbiostat/paper252. Accessed 14 August 2013.
20. van der Laan MJ, Rubin D, (2006) Targeted Maximum Likelihood Learning. The International Journal of Biostatistics 2.
21. Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, et al. (2009) Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ 87: 279-287.
22. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, et al. (2006) The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 10: 437-442.
23. Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA, (2004) Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am J Epidemiol 159: 926-934.
24. Mortimer KM, Neugebauer R, van der Laan M, Tager IB, (2005) An application of model-fitting procedures for marginal structural models. Am J Epidemiol 162: 382-388.
25. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR, (2004) Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 5: 74-79.
26. Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB, (2006) Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 43 Suppl 1: S119-122.
27. Walsh JC, Mandalia S, Gazzard BG, (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. Aids 16: 269-277.
28. Collins D, Quick JD, Musau SN, Kraushaar K, Hussein IM, (1996) The fall and rise of cost sharing in Kenya: the impact of phased implementation. Health Policy Plan 11: 52-63.
29. James CD, Hanson K, McPake B, Balabanova D, Gwatkin D, et al. (2006) To retain or remove user fees?: reflections on the current debate in low- and middle-income countries. Appl Health Econ Health Policy 5: 137-153.
30. Souteyrand YP, Collard V, Moatti JP, Grubb I, Guerma T, (2008) Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries. Aids 22 Suppl 1: S161-168.
31. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3: e438.
32. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 14: 778-784.